Annual Report

The report highlights PT Phapros Tbk's performance during the transition year of 2013, where it maintained net sales above the Rp500 billion mark despite facing negative growth due to public drug procurement changes and foreign exchange losses. The company strengthened its long-term growth foundation by investing Rp50.84 billion in fixed assets, including land and production machinery. Additionally, Phapros expanded its business base by becoming the sole distributor for Implant Cast in Indonesia and completed its high-value-added injectable production facilities. On the sustainability front, the company continued its 'Phapros Care' community development programs, focusing on mangrove reforestation, public health revitalization, and SME fostering.

Report type

Annual Report with Sustainability Disclosures

Class

Embedded

Scope

Full report

Fiscal year

2013

Period

Ends 31 December 2013

Publication date

28 March 2014

Language

English, Indonesian

Pages

 

File size